Bruker

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) Life Science, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI Life Science segment includes enabling life science tools based on magnetic resonance technology. The BSI Nano segment offers x-ray instruments that use electromagnetic radiation with wavelengths to determine the characteristics of matter and the three-dimensional (3D) structure of molecules. The BEST segment consists of conducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research, and other applications. The company was founded by Gunther Laukien in 1960 and is headquartered in Billerica, MA.

Earnings data Q1 2024

Bruker Corporation reports robust Q1 earnings and raises 2023 guidance

Bruker Corporation delivered strong financial performance in Q1 2023, with significant revenue growth and raised guidance for the full year. However, it anticipates challenges in organic growth and supply chain constraints. The company is focused on leveraging opportunities in product launches and NIH budget exposure.

Bruker reports strong Q2 performance, raises 2023 revenue guidance

Bruker's Q2 2023 performance reflects strong demand for scientific instruments and life science solutions, leading to raised revenue guidance for fiscal year 2023. While facing challenges in supply chain and NMR lead times, the company is focused on disciplined cost management. Opportunities lie in capacity growth in the BioSpin segment and increasing average pricing for the TimsTOF platform.

Bruker Corporation reports strong Q3 earnings and strategic growth focus

Bruker Corporation delivered strong financial results in Q3 2023, with raised organic revenue growth guidance for fiscal year 2023. While facing challenges in China and increased competition in the high-end proteomics mass spec market, the company remains strategically focused on operational optimization and expansion into new segments, presenting opportunities for future growth.

Bruker reports robust Q4 earnings, eyes growth amidst acquisition challenges

Bruker's strong Q4 2023 performance and full year results position them for growth in 2024 despite challenges. Strategic acquisitions, focus on organic growth, and improving cash flow highlight the company's resilience. Opportunities lie in revenue expansion, margin enhancement, and market differentiation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.

Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?

Bruker (BRKR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Bruker (BRKR) Might Surprise This Earnings Season

OSAKA, Japan--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced Raman microscopes, serving academic and industrial research customers, primarily in Japan. This acquisition fills a gap in Bruker's molecular microscopy portfolio, and Bruker is looking forward to offering fast, flexible and sensitive Nan.

Bruker Acquires Nanophoton Corporation, a Japanese Technology Leader in Research Raman Microscopy with 20 Years of Experience

TUCSON, Ariz.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that it has acquired Spectral Instruments Imaging LLC, a leader in preclinical in-vivo optical imaging systems. This acquisition fills a gap in the technology and product portfolio of the Bruker BioSpin Preclinical Imaging (PCI) division, broadening its range of preclinical solutions for disease research. Established in 2009 in Tucson, Spectral Instruments Imaging (SII) is at the forefront of technology for co-reg.

Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2023 financial results before market opening on Tuesday, February 13, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q4 2023 Earnings Webcast” hyperlink in the “Events & Presentati.

Bruker Announces Date and Time of Fourth Quarter 2023 Earnings Release and Webcast

BOSTON--(BUSINESS WIRE)---- $BRKR #BRKR--At the SLAS2024 International Conference and Exhibition, Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘Triceratops' SPR #64 Surface Plasmon Resonance (SPR) instrument. The SPR #64 system has been engineered from the bottom up to accelerate drug discovery with increased SPR throughput, leading sensitivity and data quality. In modern drug discovery, SPR is indispensable for the real-time, label-free biophysical characterization of molecular.

Bruker Introduces the Ingenious Novel ‘Triceratops' SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024

Bruker (BRKR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bruker (BRKR) Expected to Beat Earnings Estimates: Should You Buy?

Bruker Corp and JEOL Ltd are both leaders in the development and sale of innovative imaging instruments for research projects. Both companies have strong networking capabilities and are essential for new-age scientific research. While Bruker is more steady-eddy for long-term investors to buy-and-hold, I see a few catalysts that I expect will help JEOL outperform.

Bruker And JEOL: Assessing The NMR Market Leaders

Bruker Corporation BRKR recently entered into a definitive agreement to acquire a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions, Chemspeed Technologies AG. This marks a significant stride into the realm of lab automation, digitalization, and scientific software solutions.

Bruker (BRKR) to Advance in Lab Automation With New Buyout

BASEL, Switzerland--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications. The Chemspeed acquisition accelerates Bruker's entry into lab automation,.

Bruker Announces Agreement to Acquire Chemspeed

Bruker Corporation (BRKR) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)

Bruker (BRKR) announces the acquisition of Tornado Spectral Systems Inc., a global provider of chemical analysis & measurement systems for Raman spectroscopy.

Bruker's (BRKR) New Deal Widens Biopharma PAT Product Portfolio

Bruker (BRKR) announces the acquisition of the electron microscopy company Nion.

Bruker (BRKR) Expands Materials Science Research via New Deal

MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker (Nasdaq: BRKR) today announced the acquisition of Tornado Spectral Systems Inc., a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications. Tornado, with over a decade of experience in innovative and industry-proven Raman solutions, will enhance Bruker's biopharma PAT portfolio with its well-established products. Financial details were not disclosed. Tornado's patented High-Throug.

Bruker Announces Acquisition of Tornado Spectral Systems to Expand Its Biopharma Process Analytical Technology (PAT) Product Portfolio

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 42nd annual J.P. Morgan Healthcare Conference in San Francisco. Frank Laukien, Chairman, President & CEO, Mark Munch, Executive Vice President & President of Bruker Nano Group, and Gerald Herman, Executive Vice President & CFO will present on behalf of the Company on Monday, January 8th, 2024 at 8:15 AM Pacific Standard Time. A live audio webcast of the presentation will b.

Bruker Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker today announced that it has acquired Nion, a privately-held company that develops and manufactures innovative high-end scanning transmission electron microscopes (STEM). Nion was the first company to introduce aberration correction for STEM instruments with ultra-high stability for highest resolution images, and Nion is the world leader in ultra-high energy and spatial resolution electron energy-loss spectroscopy (EELS). This acquisition enhances Bruker.

Bruker Acquires Electron Microscopy Company Nion

Bruker (BRKR) 1.2 GHz AVANCE NMR spectrometer is cutting-edge equipment capable of performing high-resolution liquid and solid-state NMR studies.

Bruker (BRKR) Installs First 1.2 GHz NMR at Ohio University

COLUMBUS, Ohio--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation, the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions for life and materials research, today announced the successful installation of a 1.2 Gigahertz (GHz) NMR system at the National Gateway Ultrahigh Field NMR Center (https://gateway-nmr.osu.edu/) at The Ohio State University. Ultra-high field NMR is complementary to other structural biology technologies in that NMR can measure functional molecular dynamics and stru.

Bruker Announces First 1.2 GHz NMR Installation in the United States at The Ohio State University - Funded by the U.S. National Science Foundation

Bruker (BRKR) and Accelerate Diagnostics are set to work together to bring rapid, automated microbial identification directly from positive blood culture samples.

Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System

Accelerate Diagnostics

Working together to bring rapid, automated microbial identification directly from positive blood culture samples TUCSON, Ariz. , Nov. 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of a collaboration and quality agreement with Bruker Corporation (NASDAQ: BRKR), the provider of the market-leading MALDI Biotyper system for microbial identification.

Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 2023 Jefferies London Healthcare Conference. Gerald Herman, Executive Vice President & Chief Financial Officer will present and participate in an analyst moderated question and answer session on behalf of the Company on Tuesday, November 14, 2022 at 8:30 AM GMT (3:30 AM Eastern Time). A live audio webcast of the fireside chat will be available on the Investor Relations section of.

Bruker Corporation to Participate in the 2023 Jefferies London Healthcare Conference

Bruker (BRKR) delivers better-than-expected earnings and revenues in the third quarter of 2023.

Bruker (BRKR) Q3 Earnings and Revenues Top, '23 Sales View Up

Bruker Corporation (NASDAQ:BRKR ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Justin Ward - Investor Relations Frank Laukien - President and Chief Executive Officer Mark Munch - President, Bruker Nano Group and Corporate Executive Vice President Gerald Herman - Executive Vice President and Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Derik De Bruin - Bank of America Josh Waldman - Cleveland Research John Sourbeer - UBS Patrick Donnelly - Citi Rachel Vatnsdal - JPMorgan Jack Meehan - Nephron Research Dan Arias - Stifel Operator Greetings, ladies and gentlemen. Thank you for attending today's conference call.

Bruker Corporation (BRKR) Q3 2023 Earnings Call Transcript

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its third quarter and for the nine months ended September 30, 2023. Third Quarter 2023 Financial Results Bruker's revenues for the third quarter of 2023 were $742.8 million, an increase of 16.3% compared to $638.9 million in the third quarter of 2022. In the third quarter of 2023, revenues increased 10.9% organically year-over-year. Growth from acquisitions was 2.1%, while foreign currency.

Bruker Reports Third Quarter 2023 Financial Results

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2023 financial results before market opening on Thursday, November 2, 2023. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q3 2023 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide pres.

News for Bruker Stock (BRKR)